Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 752Pancreatic Neoplasms 665Stomach Neoplasms 387Carcinoma, Non-Small-Cell Lung 376Carcinoma, Hepatocellular 368Breast Neoplasms 316Colonic Neoplasms 279Ovarian Neoplasms 260Neoplasms 250Esophageal Neoplasms 237Neoplasm Metastasis 215Rectal Neoplasms 202Melanoma 195Lung Neoplasms 193Liver Neoplasms 180Squamous Cell Carcinoma of Head and Neck 150Carcinoma, Renal Cell 146Head and Neck Neoplasms 124Prostatic Neoplasms 123Triple Negative Breast Neoplasms 110Uterine Cervical Neoplasms 106Urinary Bladder Neoplasms 106Cholangiocarcinoma 104Endometrial Neoplasms 101Sarcoma 100Small Cell Lung Carcinoma 74Gastrointestinal Neoplasms 73Esophageal Squamous Cell Carcinoma 68Kidney Neoplasms 63Carcinoma, Transitional Cell 60

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Xeroderma Pigmentosum × Gastrointestinal × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡